---
title: "AI-developed drug rentosertib reduced patients' biological age by six years: what is known about the first 'anti-aging' medication"
description: "Insilico Medicine published in Nature Biotechnology the trial data of the AI-developed drug rentosertib: over 12 weeks, the biological age of 42 patients decreased by six years, although scientists call for caution."
date: 2026-09-08T14:34:00.000Z
lang: en
url: https://xab.info/en/posts/ai-drug-rentosertib-slowed-biological-aging-by-six-years
tags: [ai-drug, anti-aging, rentosertib, insilico-medicine, biological-aging, clinical-trial, nature-biotechnology]
publisher: "XAB.info"
---

# AI-developed drug rentosertib reduced patients' biological age by six years: what is known about the first 'anti-aging' medication

![Abstract 3D visualization of a crystal with blooming branches as a metaphor for the anti-aging effect of the AI drug rentosertib](https://xab.info/media/2026/09/08/ii-preparat-rentosertib-zamedlyaet-biologicheskoe-starenie/ii-preparat-rentosertib-zamedlyaet-biologicheskoe-starenie-1.webp)

## 🎯 Key Points

- Insilico Medicine's AI-developed drug rentosertib reduced the biological age of 42 patients by six years over 12 weeks, according to six 'aging clock' algorithms
- The results were published in Nature Biotechnology; the drug was originally developed to treat chronic lung diseases
- The scientific community emphasizes that the accuracy of 'aging clocks' remains debatable, and that no single indicator of biological age exists
- Rentosertib is in the early stages of development and requires a lengthy series of additional trials before approval

Insilico Medicine published in the scientific journal Nature Biotechnology the results of a clinical trial of the experimental drug rentosertib, developed with the help of artificial intelligence algorithms. The medication was originally created for the treatment of chronic lung diseases and the potential extension of lifespan. However, it was precisely while testing the tablets' effect on biological markers of aging that the researchers recorded an effect that no similar drug has yet been able to demonstrate: a statistically significant slowing of biological aging in the trial participants.

### How the clinical trials were conducted

The study involved 42 patients. Testing lasted 12 weeks, during which the scientists tracked the dynamics of the body's biological indicators. To assess the effect, the team used six different 'aging clocks' — specialized AI-based algorithms that determine the actual state of the body based on a combination of data: blood tests, physiological and psychological indicators. This multifactorial approach made it possible to obtain a more comprehensive picture than when relying on a single marker.

### Results: six years off the biological age

By the end of the 12-week testing course, the algorithms recorded a positive trend: the participants' biological age decreased by an average of six years across the combined set of 'aging clocks' used. This is the first documented case in which an experimental drug has demonstrated the ability not merely to affect individual biomarkers, but to shift the integral assessment of a person's biological age in the direction of 'rejuvenation.' The publication of the data in Nature Biotechnology adds further weight to the results, as the journal undergoes rigorous peer review.

### Contradictory data

Despite the high profile of the results, the scientific community urges a measured assessment of the methodology. The key problem is that the accuracy of the 'aging clocks' themselves — algorithms that measure chemical changes in DNA or protein levels in the blood — remains a subject of active scientific debate. There is still no single universally accepted indicator of a person's biological age in the world, which means that different models may yield diverging estimates. Some researchers warn that attempts to artificially alter aging marker readings could potentially damage the body's natural restorative functions. Thus, the interpretation of 'minus six years' as genuine rejuvenation is contested: some specialists regard it as a shift in the readings of a specific model, rather than as a proven biological effect.

### Prospects and limitations

The drug rentosertib is in the early stages of development. Before it can receive official approval for use, it must undergo a lengthy series of additional trials, including expanded phases of clinical research with a larger sample size and a longer observation period. Even if the effect is confirmed at scale, questions of long-term safety and potential impact on natural regeneration mechanisms will remain central for regulatory authorities. Nevertheless, the publication in Nature Biotechnology cements rentosertib's position as the first drug for which a measurable shift in biological age has been recorded, and opens a new direction in geriatric pharmacology.

## 🔍 Fact-Check Verification

- [AI created an anti-aging drug: how the new medication rejuvenates people](https://www.rbc.ua/ukr/news/shi-stvoriv-liki-vid-starosti-k-noviy-preparat-1788871734.html) - Подтверждает публикацию в Nature Biotechnology, 42 пациента, 12 недель, шесть часов старения, компанию Insilico Medicine и препарат rentosertib.
- [AI created the drug rentosertib, which slows aging](https://vc.ru/id69595/3127368-ii-sozdal-preparat-rentosertib-zamedlyayushchiy-starenie) - Совпадает по названию препарата, компании и основному тезису о замедлении старения.
- [AI-developed drug proved capable of slowing aging](https://www.rbc.ru/technology_and_media/08/09/2026/6a9f567a15df81fbe687fede) - Датируется 08.09.2026, подтверждает актуальность публикации и основной факт.
- [AI helped create a drug that reduced patients' biological age by six years](https://zn.ua/TECHNOLOGIES/ii-pomoh-sozdat-preparat-kotoryj-snizil-biolohicheskij-vozrast-patsientov-na-shest-let.html) - Уточняет конкретную цифру — снижение биологического возраста на шесть лет, что согласуется с контекстом остальных источников.

## ❓ FAQ

### Q: What is the drug rentosertib and who developed it?
**A:** Rentosertib is an experimental drug by Insilico Medicine, created with the help of artificial intelligence algorithms. It was originally developed to treat chronic lung diseases and potentially extend lifespan.

### Q: How many patients took part in the trial and how long did it last?
**A:** 42 patients took part in the clinical trial. The testing course lasted 12 weeks.

### Q: How was the anti-aging effect measured?
**A:** The researchers used six different 'aging clocks' — AI-based algorithms that determine the state of the body based on blood tests, physiological and psychological indicators. Across the combined set of these models, the participants' biological age decreased by an average of six years.

### Q: Can the drug be considered ready for use?
**A:** No. Rentosertib is in the early stages of development and must undergo a lengthy series of additional trials before it can receive official approval for use.

### Q: Why are scientists calling for caution?
**A:** The accuracy of 'aging clocks' remains a subject of scientific debate, no single universally accepted indicator of biological age exists, and attempts to artificially alter aging markers could potentially damage the body's natural restorative functions.